Acute Myocardial InfarctionMIRON-RUPTURENCT06450912
Novel Imaging Biomarkers for Mechanical Complications in Acute Myocardial Infarction
An observational study of Acute Myocardial Infarction and Hemorrhagic Myocardial Infarction, run by Rohan Dharmakumar at 1 site in United States.
Trial summary
Hemorrhagic Myocardial infarctions are at high risk for mechanical complications including cardiac rupture. Prediction of vulnerable myocardial segments is an important step for the stratification of hemorrhagic MI patients. Read more about this study
- Who is it for?
- Ages 18 to 79 years
- Conditions the study is for
- Acute Myocardial Infarction, Hemorrhagic Myocardial Infarction, Myocardial Stunning
- How many people
- 250 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jun 2022to 1 Jun 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 79 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of individuals aged 18 to 80 who have been diagnosed with acute ST-elevation myocardial infarction (STEMI) and are scheduled for emergency percutaneous coronary intervention (PCI).
Who may be able to join
- Index STEMI
- Primary PCI
- Able to complete Cardiac MR - STRAIN Protocol
Who cannot join
- Contraindication to CMR (Contrast Hypersensitivity, Metallic Implants, Abnormal Rhythms, breathing difficulties)
Trial locations and contacts
1 site in 1 country.
United States1 site
Krannert Cardiovascular Research Center, Indiana University School of Medicine
Indianapolis, Indiana, 46202
About this study
Official title: WSI Ratio as a Biomarker for Mechanical Complication of Hemorrhagic MI
Hemorrhagic Myocardial infarctions are at high risk for mechanical complications including cardiac rupture. Prediction of vulnerable myocardial segments is an important step for the stratification of hemorrhagic MI patients. Wall motion index ratio is an important parameter to determine regions of high vulnerability within the 17-segment LV model of hemorrhagic MI.
- Conditions
- Acute Myocardial Infarction, Hemorrhagic Myocardial Infarction, Myocardial Stunning, Myocardial Hemorrhage, Myocardial Reperfusion Injury, Myocardial Rupture (Post Infarct)
- Medical subject headings
- Myocardial Stunning, Myocardial Reperfusion Injury, Heart Rupture, Post-Infarction
What is being measured
The primary outcome is the main question the study is designed to answer.
Wall Strain Index for Potential Detection of Intramyocardial Hemorrhage
Difference in Wall Strain Index values between patients with intramyocardial hemorrhage and those without, confirmed by cardiac MRI.
Measured: 48 hours Post-PCI
Wall Strain Index in Detecting the Severity of Intramyocardial Hemorrhage
Relationship between initial Wall Strain Index measurements and the volume of intramyocardial hemorrhage quantified by cardiac MRI
Measured: 48 hours Post-PCI
Wall Strain Index Ratio in Identification of Vulnerable LV Segments for Cardiac Rupture
Wall Strain Index Ratio for circumferential and longitudinal strain in identifying vulnerable hemorrhagic left ventricular segments at risk for rupture
Measured: 48 hours Post-PCI
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2024
- Study start1 Jun 2022
- Primary completion1 Jun 2024
- Study completion1 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myocardial InfarctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 250 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rohan Dharmakumar
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Rohan Dharmakumar, Indiana University
- Investigators
- Rohan Dharmakumar, PhD, Study director, Indiana UniversityKeyur P Vora, MD FACC, Principal investigator, Indiana University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06450912
- Sponsor's protocol ID
- 19978e
- Acronym
- MIRON-RUPTURE
- Status last verified
- Jan 2026
- First submitted
- 4 Jun 2024
- Last updated
- 14 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- WSI Ratio as a Biomarker for Mechanical Complication of Hemorrhagic MI
- ClinicalTrials.gov ID
- NCT06450912
- Acronym / sponsor ID
- MIRON-RUPTURE / 19978e
- Conditions
- Acute Myocardial Infarction, Hemorrhagic Myocardial Infarction, Myocardial Stunning, Myocardial Hemorrhage, Myocardial Reperfusion Injury, Myocardial Rupture (Post Infarct)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 250 participants (actual)
- Lead sponsor
- Rohan DharmakumarUniversity, hospital or other
- Study start
- 1 Jun 2022 (actual)
- Primary completion
- 1 Jun 2024 (actual)
- Study completion
- 1 Jun 2024 (actual)
- First posted
- 10 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hemorrhagic Myocardial infarctions are at high risk for mechanical complications including cardiac rupture. Prediction of vulnerable myocardial segments is an important step for the stratification of hemorrhagic MI patients. Wall motion index ratio is an important parameter to determine regions of high vulnerability within the 17-segment LV model of hemorrhagic MI.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 79 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of individuals aged 18 to 80 who have been diagnosed with acute ST-elevation myocardial infarction (STEMI) and are scheduled for emergency percutaneous coronary intervention (PCI).
Key inclusion criteria (3 listed)
- Index STEMI
- Primary PCI
- Able to complete Cardiac MR - STRAIN Protocol
Key exclusion criteria (1 listed)
- Contraindication to CMR (Contrast Hypersensitivity, Metallic Implants, Abnormal Rhythms, breathing difficulties)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Wall Strain Index for Potential Detection of Intramyocardial Hemorrhage
Time frame: 48 hours Post-PCI
Difference in Wall Strain Index values between patients with intramyocardial hemorrhage and those without, confirmed by cardiac MRI.
Wall Strain Index in Detecting the Severity of Intramyocardial Hemorrhage
Time frame: 48 hours Post-PCI
Relationship between initial Wall Strain Index measurements and the volume of intramyocardial hemorrhage quantified by cardiac MRI
Wall Strain Index Ratio in Identification of Vulnerable LV Segments for Cardiac Rupture
Time frame: 48 hours Post-PCI
Wall Strain Index Ratio for circumferential and longitudinal strain in identifying vulnerable hemorrhagic left ventricular segments at risk for rupture
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Acute Myocardial Infarction
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
Myocardial Infarction, Myocarditis Acute
Enrolling by invitationPhase 3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rohan Dharmakumar, PhD study director
Indiana University
Keyur P Vora, MD FACC principal investigator
Indiana University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Myocardial Infarction and Hemorrhagic Myocardial Infarction, run by Rohan Dharmakumar at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Wall Strain Index for Potential Detection of Intramyocardial Hemorrhage (time frame: 48 hours Post-PCI). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2026.